Humana（HUM）FY2025年报排雷报告

框架：唐朝《手把手教你读财报》+ Schilit《Financial Shenanigans》+ Beneish M-Score

核心理念："财报是用来排除企业的"

数据来源：SEC EDGAR 10-K原文 + Yahoo Finance

❌ 评级F——现金转换有三项失败

一句话：Humana的F评级来自三项失败——应收连续两年跑赢营收、经营现金流68.9%塌缩、商誉+无形资产占权益61%。失败背后的业务基本面在10-K里都看得到：赔付率跳升到90.2%因为医疗成本上涨快于保费、公司计提$4.49亿价值创造费用、退出雇主团体商业医疗产品业务。净利润下滑到$11.9亿——建立在$1,296.6亿营收上——0.9%的净利率。M-Score因标准格式数据不足而无法计算。这是管理式医疗的盈利能力挤压，不是操纵担忧。

一、Medicare Advantage时代的管理式医疗

10-K："Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health delivering the care and service they need, when they need it."

Humana运营两个报告分部：

保险分部——10-K："Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits."

CenterWell分部——初级护理、药房解决方案和家庭健康服务，作为公司价值医疗战略的一部分进行整合。

营收仍在增长，但盈利引擎正在被挤压。10-K MD&A："Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability."

FY2025两个比率都朝错的方向：赔付率升40bp到90.2%，运营成本率升20bp到12.0%。这60个基点的合计恶化建立在$1,296.6亿营收上，对营业利润是约$7.8亿的打击——正好匹配报告的适度利润增长。

10-K MD&A利润表："Total revenues 129,664 117,761 11,903 10.1 % Operating expenses: Benefits 110,812 100,664 10,148 10.1 % Operating costs 15,450 13,696 1,754 12.8 %"

赔付费用增长10.1%（与营收增长匹配），但运营成本增长12.8%，快于营收——吞噬了适度的定价收益。

价值创造倡议和减值费用

10-K："In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions. As a result of these initiatives, we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively."

10-K拆分了FY2025的$4.49亿："$329 million in severance and other employee related charges in connection with workforce optimization in 2025... as well as $40 million... in asset impairments in 2025... The remainder of the 2025 charges primarily relate to external consulting spend."

除此之外："we recorded impairment charges of $253 million, $200 million and $91 million in 2025, 2024 and 2023, respectively. The impairment charges included impairment of indefinite-lived intangible assets for $128 million, $200 million and $55 million in 2025, 2024 and 2023, respectively."

FY2025价值创造费用加减值的累计税前拖累约$7亿——对已被挤压的盈利基础的有意义压力。

退出雇主团体商业业务

10-K："During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs... Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans."

二、现金流：急剧下滑

CFFO从FY2024的$29.7亿塌缩69%到FY2025的仅$9.2亿——触发A3失败。净利润基本持平在$11.9亿，但现金转换一年内从2.46倍降到0.78倍。下降反映了营运资本逆风：应收从$27.0亿增长到$32.7亿（+21%），部分因营收增速超过保费收款，部分因州政府Medicaid应收上升。

三、18项排雷检查

收入质量

A2失败：应收FY2025增长20.8% vs 营收+10.1%，FY2024应收增长32.3% vs 营收+10.7%。连续两年应收跑赢营收是机械性失败。对保险公司来说，很多应收余额代表来自CMS（Medicare）、州Medicaid机构和再保险的应收——但即便如此，增长速度超出保费量能解释的范围。

A3失败：营收增长10.1%而CFFO下降68.9%。这是筛选集里最大的单项营收-现金背离。

费用质量

HUM的利润表使用"赔付 + 运营成本"而非"COGS + SG&A"，所以毛利率和SG&A检查无法干净映射到yfinance字段。

现金流质量

C1关注：CFFO/NI 0.78低于1.0阈值。稳定年份，Humana因大额精算准备金（特别是IBNR）而产生远高于净利润的CFFO。FY2025比率跌破1表明不寻常的营运资本消耗。

C4通过：现金和短期投资$199亿舒适地覆盖$124亿总债务。然而，大部分现金是监管下的子公司资本，支持保险准备金——不能自由用于满足母公司义务。

资产负债表

D1失败：商誉$96.9亿加无形资产$11.3亿 = $108.2亿，等于$176.6亿权益基数的61%。商誉集中在CenterWell和Home Solutions业务。PwC将Home Solutions报告单元商誉列为关键审计事项："the Company's goodwill balance was $9.7 billion as of December 31, 2025."

并购风险

商誉+无形同比下降2%，由$1.28亿无限期无形资产减值驱动。

Beneish M-Score

四、10-K原文中的关键风险

1. 定价和医疗成本趋势风险（首位风险）。 10-K："If we do not design and price our products properly and competitively, if the premiums we charge are insufficient to cover the cost of health care services delivered to our members... our profitability may be materially adversely affected." 10-K继续："Generally, premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums."

2. Humana无法控制的成本驱动因素长名单。 10-K列出了可能导致实际医疗成本超出预测的因素："increased use of medical facilities and services, and the increased cost of such services; increased use or cost of prescription drugs, including specialty prescription drugs; the introduction of new or costly treatments, prescription drugs, or new technologies; our membership mix..."

3. 竞争激烈和低进入壁垒。 10-K："We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do... We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period."

4. IBNR未付赔款估计——第一项关键审计事项。 PwC："the Company's incurred but not yet reported benefits payable (IBNR) was $6.6 billion as of December 31, 2025. Management develops its estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience." $66亿的准备金是Humana资产负债表上最大的估计之一，任何假设变化直接流入净利润。

5. 家居解决方案商誉减值风险——第二项关键审计事项。 10-K："the Company's goodwill balance was $9.7 billion as of December 31, 2025"——PwC特别指出Home Solutions报告单元和CON无形资产为CAM。

五、Altman Z-Score和F-Score

六、总结

评级：F。三项失败（A2、A3、D1）反映真实的运营压力。

Humana的F评级追踪的是10-K全文记录的真实业务恶化。赔付率扩张到90.2%、运营成本率到12.0%，合计60bp的挤压消耗了10.1%营收增长的大部分。价值创造费用$4.49亿加上减值$2.53亿减少了报告营业利润。CFFO从$29.7亿塌缩到$9.2亿——69%下降——因为营运资本吸收现金、应收增长21%。

与这些压力相对，缓解因素适度但真实：应计比率干净的0.5%、现金和短期投资$199亿超过总债务$124亿（尽管大部分受子公司监管）、以及退出雇主团体商业业务移除了一个长期亏损者。根据PwC的关键审计事项，Home Solutions商誉仍在观察，IBNR未付赔款$66亿是资产负债表上最大的单项估计风险。

这是一个管理式医疗的盈利能力故事。F评级捕捉的是现金转换的恶化和商誉风险，不是任何操纵担忧——尽管无法计算的M-Score意味着一个关键的操纵检查缺席了证据基础。

财报是起点，不是终点。

⚠️ **免责声明**：本报告基于Humana 2025 10-K年报原文（SEC EDGAR）及Yahoo Finance公开财务数据，运用排雷框架进行分析，不构成任何投资建议。投资有风险，决策需自行判断。

数据来源：SEC EDGAR 10-K (Filed 2026-02-19) + Yahoo Finance

审计师：PricewaterhouseCoopers LLP（无保留意见，2项关键审计事项）